How Long CJC-1295 No DAC Stays in System — Clearance Timeline
The single biggest misconception about CJC-1295 no DAC is that it behaves like its DAC-modified counterpart. It doesn't. CJC-1295 without Drug Affinity Complex (DAC) has a plasma half-life of approximately 30 minutes. Meaning the peptide reaches peak concentration within 10–15 minutes post-injection and falls to half its initial level within 30 minutes. By comparison, CJC-1295 with DAC extends that half-life to 6–8 days, fundamentally altering how the compound interacts with growth hormone-releasing hormone (GHRH) receptors and dictating entirely different administration schedules.
We've worked with research-grade peptides across hundreds of protocols. Understanding how long CJC-1295 no DAC stays in system determines dosing frequency, expected pulsatile response patterns, and whether it aligns with your experimental design. The difference isn't subtle. It's the distinction between a compound that mimics natural GH pulses and one that creates sustained elevation.
How long does CJC-1295 no DAC stay in your system?
CJC-1295 no DAC has a half-life of approximately 30 minutes, with detectable plasma levels declining to negligible within 2–4 hours post-administration. This short duration mimics the body's natural GHRH pulsatility and requires multiple daily dosing if sustained elevation is the goal. Unlike the DAC-modified version, which remains active for days, CJC-1295 no DAC clears rapidly through renal filtration and enzymatic degradation.
The clearance timeline for CJC-1295 no DAC follows predictable pharmacokinetics. After subcutaneous administration, the peptide enters systemic circulation within minutes, binds to GHRH receptors in the anterior pituitary, and stimulates a sharp pulse of growth hormone release. Within 30 minutes, plasma concentrations drop by 50%. By 90–120 minutes, measurable peptide levels fall below the threshold required for receptor activation. Complete renal clearance occurs within 4–6 hours. This is not speculation; it's the mechanism that differentiates modified from unmodified GHRH analogs. The peptide's short chain structure (29 amino acids) and lack of albumin-binding modification mean it cannot persist in circulation the way DAC-conjugated variants do.
The DAC Modification: Why It Changes Everything
DAC (Drug Affinity Complex) is a synthetic chemical group attached to the lysine residue at position 15 of the CJC-1295 peptide sequence. This modification enables the peptide to bind non-covalently to serum albumin, the most abundant protein in human plasma. Albumin acts as a molecular carrier, sequestering the peptide from renal filtration and enzymatic breakdown. The result: instead of clearing within hours, CJC-1295 with DAC remains bound to albumin for 6–8 days, creating sustained GHRH receptor activation and continuous growth hormone elevation rather than pulsatile release.
Without DAC, CJC-1295 behaves like endogenous GHRH. It binds to pituitary receptors, triggers a GH pulse, and is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV) and cleared through the kidneys. The unmodified peptide's half-life of 30 minutes reflects this natural degradation pathway. With DAC, the peptide evades enzymatic breakdown by remaining albumin-bound in circulation, extending its effective half-life by a factor of 200–300×. This is not a minor pharmacokinetic tweak. It fundamentally alters the peptide's biological role from pulsatile signal to sustained agonist.
Our team has reviewed clearance timelines across dozens of GHRH analogs. The DAC modification is the single most impactful structural change in this class. More so than amino acid substitutions, more so than C-terminal extensions. If your research model depends on mimicking natural GH pulsatility, CJC-1295 with DAC is the wrong tool. If sustained elevation is the goal, CJC-1295 no DAC requires dosing 2–3 times daily to maintain therapeutic levels, which most protocols find impractical.
Dosing Frequency and Pharmacokinetic Implications
The 30-minute half-life of CJC-1295 no DAC dictates a dosing schedule that mirrors endogenous GHRH pulses. In physiological terms, the hypothalamus releases GHRH in discrete pulses. Primarily during deep sleep and in response to exercise or fasting. A single administration of CJC-1295 no DAC replicates one pulse. To sustain elevated GH over 24 hours, researchers typically dose 2–3 times daily at 100–200 mcg per injection. By contrast, CJC-1295 with DAC is administered once weekly at 1–2 mg due to its extended half-life and sustained receptor occupancy.
The short clearance window for CJC-1295 no DAC offers experimental advantages in controlled settings. Pulsatile GH release more closely mirrors natural endocrine rhythms, which may reduce negative feedback suppression of endogenous GHRH and somatostatin compared to continuous elevation. Research published in the Journal of Clinical Endocrinology & Metabolism has demonstrated that pulsatile GH administration preserves receptor sensitivity and metabolic responsiveness better than sustained infusion. The same principle applies to GHRH analogs.
Here's what we've found working with research-grade peptide protocols: if your experimental design requires tight temporal control over GH peaks. For instance, measuring anabolic response windows or studying circadian GH patterns. CJC-1295 no DAC's rapid clearance is a feature, not a limitation. If ease of administration and sustained exposure matter more, the DAC version is more practical. The peptides are not interchangeable.
CJC-1295 No DAC vs Ipamorelin vs MOD-GRF(1-29): Clearance Comparison
CJC-1295 No DAC
~30 minutes
GHRH analog. Binds pituitary GHRH receptors to stimulate GH pulse
2–3× daily at 100–200 mcg
Negligible plasma levels by 2–4 hours; complete renal clearance within 6 hours
Best for replicating natural pulsatile GH release; requires frequent dosing but preserves receptor sensitivity
CJC-1295 With DAC
6–8 days
GHRH analog with albumin-binding modification. Sustains GH elevation
Once weekly at 1–2 mg
Detectable levels persist 10–14 days; albumin-bound peptide clears slowly
Practical for long-term protocols but creates non-physiological sustained GH elevation
Ipamorelin
~2 hours
Ghrelin mimetic. Binds ghrelin receptors (GHS-R1a) to release GH
2–3× daily at 200–300 mcg
Plasma levels drop below threshold by 4–6 hours
Often stacked with CJC-1295 no DAC; complementary pulsatile mechanisms with minimal cortisol/prolactin effects
MOD-GRF(1-29)
Modified GHRH. Identical to CJC-1295 no DAC
Identical clearance to CJC-1295 no DAC
Functionally interchangeable with CJC-1295 no DAC; naming differs by supplier but peptide sequence is the same
Key Takeaways
CJC-1295 no DAC has a half-life of approximately 30 minutes, with complete clearance from the system occurring within 4–6 hours post-administration.
The DAC modification extends the peptide's half-life to 6–8 days by enabling albumin binding, fundamentally altering dosing schedules and physiological effects.
Rapid clearance of CJC-1295 no DAC mimics natural GHRH pulsatility, requiring 2–3 daily doses to maintain elevated GH levels throughout the day.
Enzymatic degradation by DPP-IV and renal filtration are the primary clearance pathways for unmodified CJC-1295, not hepatic metabolism.
Pulsatile GH release from CJC-1295 no DAC preserves receptor sensitivity better than sustained elevation from the DAC version, per endocrinology research.
MOD-GRF(1-29) and CJC-1295 no DAC are functionally identical peptides with the same clearance timeline and mechanism. Naming differs by supplier only.
What If: CJC-1295 No DAC Scenarios
What If I Dose CJC-1295 No DAC Only Once Per Day?
You will experience a single GH pulse followed by a return to baseline within 4–6 hours. Given the 30-minute half-life, once-daily dosing provides inadequate coverage for sustained anabolic or metabolic effects. Research models typically dose 2–3× daily to replicate the body's natural GHRH pulse frequency. Once before morning training, once mid-afternoon, and optionally once before sleep to align with nocturnal GH secretion peaks.
What If I Accidentally Use CJC-1295 With DAC When I Intended to Use the No-DAC Version?
The effects will last significantly longer than expected. CJC-1295 with DAC creates sustained GH elevation for 6–8 days rather than a 2–4 hour pulse, potentially leading to non-physiological endocrine feedback and receptor desensitisation if dosed at the frequency intended for the no-DAC version. If this occurs, discontinue dosing and allow the peptide to clear fully before resuming the correct compound. The albumin-bound DAC version will remain active regardless of subsequent dosing adjustments.
What If I Want to Combine CJC-1295 No DAC With Ipamorelin?
This is a common stacking approach in research protocols. CJC-1295 no DAC (a GHRH analog) and ipamorelin (a ghrelin mimetic) act on different receptor pathways. GHRH receptors and ghrelin receptors (GHS-R1a) respectively. Creating a synergistic GH pulse when co-administered. Both peptides have short half-lives (30 minutes for CJC-1295 no DAC, ~2 hours for ipamorelin), so they are typically dosed together 2–3 times daily at 100–200 mcg CJC-1295 no DAC + 200–300 mcg ipamorelin per injection. The combined effect produces a larger GH pulse than either peptide alone without increasing cortisol or prolactin, which is a documented advantage of ipamorelin over earlier ghrelin analogs like GHRP-6.
What If I Miss a Scheduled Dose of CJC-1295 No DAC?
Simply resume with the next scheduled dose. Because the peptide clears completely within hours, there is no residual level to 'build on'. Each dose creates an independent GH pulse. Missing one dose means missing one pulse, but it does not disrupt subsequent dosing or require adjustment. This is fundamentally different from CJC-1295 with DAC, where missed doses can create gaps in sustained coverage that may take days to re-establish.
The Blunt Truth About CJC-1295 Naming Confusion
Here's the honest answer: the peptide marketed as 'CJC-1295 no DAC' is not technically CJC-1295 at all. The original CJC-1295 peptide, as defined in the scientific literature, includes the DAC modification. That's what made it novel when it was first synthesised. What suppliers call 'CJC-1295 no DAC' is actually modified GRF(1-29), also known as MOD-GRF(1-29) or tetrasubstituted GRF(1-29). The peptides are functionally identical in sequence and mechanism, but the naming is commercially driven, not scientifically accurate. If a supplier lists both 'CJC-1295 no DAC' and 'MOD-GRF(1-29)' as separate products, they are selling the same compound under two names. The clearance timeline, dosing, and receptor activity are identical. This naming confusion has persisted for over a decade in the research peptide market, and it's unlikely to be corrected. But knowing the distinction matters when interpreting published research or comparing supplier offerings.
Renal Clearance Mechanisms and Detection Windows
CJC-1295 no DAC is eliminated primarily through glomerular filtration in the kidneys. The peptide's molecular weight (3,600 Da) falls below the renal filtration threshold (60,000 Da), allowing it to pass freely through the glomerular basement membrane into the urine. Enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) in plasma further accelerates clearance by cleaving the peptide into smaller inactive fragments before renal excretion. This dual-clearance pathway. Enzymatic degradation plus renal filtration. Is why how long CJC-1295 no DAC stays in system is measured in hours, not days.
Detection windows for CJC-1295 no DAC in biological samples are correspondingly short. Plasma concentrations fall below the limit of detection for standard immunoassays within 6–8 hours post-dose. Urinary metabolites may remain detectable slightly longer (12–24 hours) depending on assay sensitivity, but the intact peptide clears rapidly. For research applications requiring controlled temporal exposure, this short detection window is advantageous. It allows precise mapping of GH response kinetics without confounding carryover effects from previous doses. For those exploring research-grade peptides with complementary mechanisms, our CJC1295 Ipamorelin 5MG 5MG formulation provides a pre-measured stack optimised for pulsatile GH protocols.
The absence of hepatic metabolism as a primary clearance route is noteworthy. Unlike many small-molecule drugs, peptides are not metabolised extensively by cytochrome P450 enzymes in the liver. This means hepatic impairment has minimal impact on CJC-1295 no DAC clearance, whereas renal impairment would significantly extend the peptide's half-life and require dose adjustments in research models with compromised kidney function.
How long CJC-1295 no DAC stays in system is not the same question as how long its effects persist. The peptide itself clears within hours, but the GH pulse it triggers can elevate serum GH levels for 2–4 hours post-injection, with downstream effects on IGF-1 synthesis lasting 12–24 hours. The peptide is the trigger; the hormone cascade it initiates outlasts the peptide's presence in circulation. This distinction matters when interpreting experimental timelines. Measuring residual peptide in plasma tells you nothing about whether the biological response is still active.
The reality is this: if you're working with CJC-1295 no DAC, plan your protocol around a compound that disappears fast. That's not a flaw. It's the feature that makes it useful for studying pulsatile endocrine dynamics rather than sustained pharmacological elevation. The DAC version serves a different experimental purpose entirely, and conflating the two leads to flawed study design and irreproducible results. At Real Peptides, we synthesise every peptide with exact amino-acid sequencing and provide third-party purity verification because reproducibility depends on knowing exactly what you're working with. Not just the name on the vial. You can explore our commitment to precision across our full peptide collection and see how small-batch synthesis guarantees consistency that bulk manufacturing cannot.
Frequently Asked Questions
CJC-1295 no DAC has a half-life of approximately 30 minutes, with plasma concentrations dropping to negligible levels within 2–4 hours post-administration. Complete renal clearance occurs within 4–6 hours. This short duration requires multiple daily dosing (typically 2–3 times per day) to maintain elevated GH levels, unlike the DAC-modified version which remains active for 6–8 days.
No — the 30-minute half-life of CJC-1295 no DAC makes once-weekly dosing ineffective. Without the albumin-binding DAC modification, the peptide clears completely within hours, providing only a single GH pulse per dose. To sustain elevated GH throughout the week, the no-DAC version requires 2–3 daily administrations at 100–200 mcg per injection, which is fundamentally incompatible with weekly dosing schedules.
CJC-1295 no DAC and MOD-GRF(1-29) are the same peptide with identical amino acid sequences, clearance timelines, and mechanisms. The naming differs by supplier, but both refer to modified growth hormone-releasing hormone (GHRH) without the Drug Affinity Complex modification. They are functionally interchangeable in research protocols — the peptide that clears in 4–6 hours is always the unmodified version, regardless of which name appears on the label.
CJC-1295 no DAC is eliminated through two primary pathways: enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) in plasma, and glomerular filtration in the kidneys. The peptide’s molecular weight (~3,600 Da) allows it to pass freely through the renal filtration barrier into urine. Hepatic metabolism plays a minimal role — renal impairment would extend clearance time, but liver function has negligible impact on how long CJC-1295 no DAC stays in system.
Standard drug panels do not test for peptides like CJC-1295 no DAC. Specialised peptide assays can detect the compound in plasma for 6–8 hours and in urine for up to 24 hours post-dose, but these tests are not part of routine screening protocols. Detection requires targeted immunoassays or mass spectrometry specifically looking for GHRH analogs — the peptide is not a controlled substance and is not included in athletic anti-doping panels unless peptide-specific testing is requested.
You will experience sustained GH elevation for 6–8 days instead of a 2–4 hour pulse. The DAC-modified version binds to albumin and remains in circulation far longer, creating non-physiological continuous GHRH receptor activation. If this occurs, discontinue dosing immediately and allow the peptide to clear fully — the albumin-bound version cannot be ‘reversed’ and will remain active regardless of subsequent actions. Resuming the correct no-DAC compound before the DAC version clears risks receptor desensitisation from prolonged stimulation.
The peptide itself clears within 4–6 hours, but the GH pulse it triggers elevates serum growth hormone for 2–4 hours post-injection. Downstream effects on IGF-1 synthesis and anabolic signalling persist for 12–24 hours. The peptide is the signal; the endocrine cascade it initiates outlasts the peptide’s presence in plasma — measuring residual peptide levels does not indicate whether the biological response is still active.
CJC-1295 no DAC is frequently stacked with ipamorelin in research protocols. The two peptides act on different receptor systems (GHRH receptors and ghrelin receptors respectively) and create a synergistic GH pulse when co-administered. Both have short half-lives and are typically dosed together 2–3 times daily at 100–200 mcg CJC-1295 no DAC + 200–300 mcg ipamorelin per injection. This combination produces a larger GH response than either peptide alone without increasing cortisol or prolactin elevation.
CJC-1295 no DAC has been studied in controlled research settings for extended periods with minimal adverse effects reported in published trials. The pulsatile GH release it creates more closely mirrors natural endocrine rhythms than sustained elevation, which may preserve receptor sensitivity and reduce negative feedback suppression. However, safety in long-term use depends on dosing frequency, baseline endocrine function, and concurrent interventions — this is a research compound, and long-term human safety data outside controlled trials is limited.
Yes — renal impairment significantly extends the clearance timeline for CJC-1295 no DAC. Because glomerular filtration is the primary elimination pathway, compromised kidney function reduces the peptide’s clearance rate and prolongs its half-life. Research models with renal dysfunction would require dose adjustments to avoid accumulation and prolonged receptor stimulation. Hepatic impairment has minimal impact since peptides are not extensively metabolised by liver enzymes.